Objective: In this work, we evaluated the association of human immunodeficiency virus (HIV) infection and methamphetamine (METH) use with mitochondrial injury in the brain and its implication on neurocognitive impairment.
Introduction
Mitochondria are the main organelles responsible for synthesizing energy in the form of ATP for metabolic and cellular processes throughout the body and in the central nervous system (CNS) [1] . In eukaryotic cellular respiration, postglycolytic reactions occur in mitochondria, making mitochondria at risk to damage by reactive oxygen species (ROS). Oxidative damage caused by ROS can lead to mitochondrial DNA (mtDNA) mutations and deletions. Previous studies have explored the relationships between mtDNA deletions, neurodegenerative diseases, and mental illnesses [2] [3] [4] . However, little is known about mitochondrial and neurocognitive dysfunction in the setting of human immunodeficiency virus (HIV) type 1 infection.
The most frequently identified mtDNA deletionaccounting for about 40% of all mtDNA deletions -is a 4977 bp deletion that affects RNA transfer and respiratory chain genes known as the 'common deletion' [5] . The 'common deletion' results in defective mitochondrial function and is often found in higher amounts in the brain tissue of individuals with neurodegenerative diseases, substance abuse, or older age [6] [7] [8] . Although each mitochondrion carries multiple copies of its genome in response to the risk incurred by ROS, somatic changes in mtDNA can proliferate within the mtDNA population over time. Accumulation of mtDNA carrying deletions within a cell can lead to reduced energy synthesis and overall mitochondrial network dysfunction.
Neurocognitive dysfunction is a common complication of HIV disease. HIV may enter the CNS and establish a latent infection. In some individuals, productive infection occurs in the CNS leading to inflammation and eventually to HIV-related brain injury, affecting pathways involved in learning, memory, attention/working memory, and executive functioning [9] . Previous studies have also demonstrated that HIV-1-infected macrophages produce factors that suppress axonal growth and induce mitochondrial membrane depolarization. This might lead to reduced ATP production, causing additional damage to neurons [10] .
Methamphetamine (METH) use is associated with neurocognitive disorders; the neuropathogenesis of HIV-1 infection may also be exacerbated by METH use [11] . Some of the effects of METH use are apoptosis, oxidative stress, and neuroinflammation [12, 13] . METH is a prominent drug of choice among HIV-infected individuals engaging in high-risk behaviors [14] [15] [16] [17] . METH use during HIV infection is associated with increased viral loads in cerebral spinal fluid (CSF), plasma, or both; enhanced HIV-1 pathogenesis [18] ; and greater mtDNA damage [19] . In addition, METH has been shown to increase HIV-1 replication in dendritic cells [20] and monocyte-derived macrophages [21] .
In this study, we compared the levels of mtDNA and the relative proportion of the 'common deletion' in brain tissue of HIV-infected individuals with or without reported history of past METH use. We also investigated the magnitude of mitochondrial genetic defects in relation to neurocognition. Given our previous work demonstrating the correlation between cell-free CSF mtDNA levels and neurocognitive performance [22] , we also investigated cell-free CSF mtDNA in these groups. Elucidation of the relationship between METH use and HIV infection on mtDNA may help improve our understanding of the role of mitochondrial injury in HIVassociated neurocognitive disorders.
Materials and methods

Study cohorts
Brain tissue samples containing white and gray matter from Brodmann areas 7, 8, 9, and 46 were obtained from the National NeuroAIDS Tissue Consortium (NNTC). The frontal lobe regions areas 8, 9, and 46 were requested based upon previous work demonstrating the role of oxidative stress in neurodegeneration and METH effects on the frontal lobe [23] [24] [25] . All samples were from unique individuals, except for some paired areas 7 and 8 tissue samples, which came from the same participants. Samples were obtained from subjects classified into three groups: HIV-infected individuals with reported history of past METH use (HIVþMETHþ, n ¼ 16), HIV-infected individuals with no reported history of past METH use (HIVþMETHÀ, n ¼ 11), and HIV-negative controls (HIVÀMETHÀ, n ¼ 30). We also obtained CSF samples when available from these subjects. Participants were classified into the same three groups as above: HIVþMETHþ (n ¼ 15), HIVþMETHÀ (n ¼ 26), and HIVÀMETHÀ (n ¼ 17). Participants with known Alzheimer's disease [HIVþMETHÀ (n ¼ 1), HIVþMETHþ (n ¼ 3), and HIVÀMETHÀ (n ¼ 4)] were excluded from analysis, as Alzheimer's disease is associated with higher levels of mitochondrial DNA deletions [26, 27] . Clinical assessments, sociodemographical variables, and neuropsychological performance evaluations were obtained from assessments performed during the premortem period.
Neuropsychological assessments
Participants underwent neuropsychological testing using neuropsychological test battery of seven ability areas summarized by the Global Deficit Score (GDS), a continuous score ranging from 0 (no impairment) to 5 (severest impairment) [28, 29] . An individual with a GDS score of greater than 0.5 was deemed to have neurocognitive impairment [22] . In this study, we analyzed GDS as a continuous variable to measure neuropsychological performance.
Brain removal and storage All brain specimens were obtained with a postmortem interval of under 24 h (median ¼ 13.4 h). The entire brain was removed, weighed, bisected longitudinally, snap frozen, and then sectioned according to NNTC brainprocessing protocols. The frozen tissue samples were transported on dry ice and stored at À808C until the samples were processed. Frozen CSF samples were treated in a similar manner.
DNA extraction
Separate DNA extractions were performed from 25 mg of white matter and gray matter from each sample using the QIAamp DNA Mini Kit (Qiagen, Venlo, Holland) from areas 7, 8, 9, and 46. The manufacturer's protocol was followed except that the DNA was eluted twice using 200 ml elution buffer each time to maximize DNA recovery. The first elution included a 5-min incubation before the final spin. Quality of the extraction, both quantification and purity of the nucleic acids, was assessed using the Nanodrop 1000 Spectrophotometer (Thermo Scientific, Waltham, Massachusetts, USA) software version 3.7.1 per manufacturer's protocol.
Quantification of mtDNA and mitochondrial injury DNA quantification was performed using the highly sensitive droplet digital PCR platform [30] . In lieu of a digestion step, we used QIAshredder (Qiagen) celllysate homogenizer on 10 ng/ml of extracted DNA in a total volume of 25 ml per manufacturer's protocol. We quantified levels of mtDNA per cell by measuring the copy numbers of the mitochondrial NADH dehydrogenase 2 (MT-ND2) (Applied Biosystems, Waltham, Massachusetts, USA) using a standard Applied Biosystems assay (Cat. # 4331182), and the cellular control gene ribonuclease P protein subunit p30 (RPP30) (Integrated DNA Technologies, Coralville, Iowa, USA), which is present in two copies per cell as described in our previous study [22] . The names and sequences of these primer-probe sets are as follows: RPP30-F (5 0 -GATTTGGACCTGCGAGCG-3 0 ), RPP30-R (5 0 -GCGGCTGTCTCC ACAAGT-3 0 ), and RPP30-P (5 0 -HEX/CTGACCTGA/ZEN/AGGCTCT/IBFQ-3 0 ). In addition, we quantified levels of HIV in the brain tissue samples by measuring the copy numbers of conserved regions in HIV-1, such as the long terminal repeat (LTR) and the gag gene (Integrated DNA Technologies), to look for any associations between HIV DNA levels in the brain and mitochondrial injury or mtDNA. The names and sequences of these primer-probe sets are as follows: 2LTR-F (5 0 -TGCCAATCAGGGAAGWAGCCTTG-3 0 ), 2LTR-R (5 0 -GAACCCACTGCTTAAGCCT-CAAT-3 0 ), and 2LTR-P (5 0 -FAM/CTGACCTGA/ ZEN/A GGCTCT/IBFQ-3 0 ) for the LTR gene, and GAG-F (5 0 -AGTTGGAGGACATCA AGCAGCCA-TGCAAAT-3 0 ), GAG-R (5 0 -TGCTATGTCAGTTCC-CCTTGGTTCTCT-3 0 ), and GAG-P (5 0 -HEX/ CTGACCTGA/ZEN/AGGCTCT/IBFQ/-3 0 ) for the gag gene.
In the brain tissue samples, we measured the relative proportion of mtDNA carrying the 'common deletion' and used it as our measurement of mitochondrial injury. We designed a primer-probe combination that targets the bridge region on the mitochondrial chromosome before and after the 4977 bp 'common deletion' (Integrated DNA Technologies) ( Fig. 1) . The names and sequences of these primer-probe sets are as follows: CD-F (5 0 -GGCTCAGGCGTTTGTGTATGAT-3 0 ), CD-R (5 0 -TATTAAACACAAACTACCACCT ACC-3 0 ), and CD-P (5 0 -FAM/ACCATTGGC/ZEN/AGCC-TAG/IBFQ-3 0 ). As a result, amplification will only occur in the presence of the deletion. For quantification, we used 50 ng of DNA when measuring the 'common deletion', and 50 pg of DNA when measuring MT-ND2. In the extracted DNA from CSF samples, we only measured MT-ND2 and RPP30, given the low levels of DNA present.
Quantification was performed in triplicate using a reaction consisting of 10 ml of 2Â Bio-Rad (Hercules, California, USA) Supermix for probes, either 1 ml of 20Â Primer/FAM MT-ND2 mix or 20Â Primer/FAM CD mix in combination with 20Â Primer/HEX RPP30 mix, 3 ml of molecular grade water, and 5 ml of shredded DNA. When we measured levels of HIV, we used a reaction consisting of 10 ml of 2Â Bio-Rad Supermix for probes, either 1 mL of 20Â Primer/FAM 2LTR mix with 20Â Primer/HEX GAG, or 20Â Primer/HEX RPP30 mix with 1 ml of molecular grade water, and 8 ml of shredded DNA. The PCR thermal cycling conditions were: initial activation at 958C for 10 min; 55 cycles at 948C for 30 s and 608C for 1 min (ramp speed 28C/s); enzyme inactivation at 988C for 10 min and a 48C hold. Droplets were read and analyzed using the Bio-Rad QX100 droplet reader and QuantaSoft software version 1.6.6. We calculated the average amount of mtDNA per cell using our cellular control. The amount of cells tested per well were calculated by dividing the amount of RPP30 copies by 2 to adjust for two copies of RPP30 present in one cell. The relative proportion of 'common deletion' was calculated by dividing the number of mitochondria carrying the 'common deletion' per cell by the total number of mtDNA copies (ND2) per cell. Separate from the brain tissue samples, levels of mtDNA in CSF were expressed in log 10 copies/ml of CSF.
Soluble and inflammatory markers in cerebral spinal fluid
We measured levels of soluble CD14 (sCD14) and soluble CD163 (sCD163) in our CSF samples using Quantikine ELISA Human sCD14 and sCD163 (R&D Systems, Minneapolis, Minnesota) following manufacturer's protocols. In addition, we measured neurofilament light (NF-L) and neopterin using the NF-Light (NF-L; Uman Diagnostics, Umea, Sweden and BRAHMS GmbH, Hennigsdorf, Germany) kits, respectively. All of these markers have been previously associated with inflammation and neurocognitive impairments in HIV infections [31] [32] [33] .
Statistical analysis
All statistical analyses were performed using R statistical software, Version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria. URL http://www.Rproject.org/). Normality of variables was assessed using the Shapiro test. Variables were either log-or square roottransformed to approximate a normal distribution. Differences in the levels of mtDNA levels per cell or relative abundance of common deletion were assessed with either a two-tailed t-test (pairwise comparisons) or by analysis of variance with a Tukey post-hoc adjustment for three-class comparisons. Univariate and multivariate association between variables were determined with either fixed-effects or mixed-effects regression analyses adjusting for repeated measures as needed.
Results
Cohort characteristics
The median age at death was 49 years. All participants were male. All HIV-infected patients both in the HIVþMETHÀ group and HIVþMETHþ group were on antiretroviral therapy (ART) when clinical and neuropsychological assessments were administered and reported until death. Neuropsychological assessments were performed on all HIV-infected participants prior to the last premortem visit. CSF, blood, lymphocyte profiles, and demographic characteristics were also collected premortem. There were no significant differences between the three study groups in relation to these variables. A summary of cohort characteristics is provided in Table 1 . Participants with known Alzheimer's disease were excluded from analysis.
Levels of mtDNA and mitochondrial injury in different brain regions
When comparing the levels of mtDNA in white matter between sampled Brodmann areas 8, 9, and 46 we found that area 46 had significantly higher levels of mtDNA when compared with area 8 (P < 0.01) and area 9 (P < 0.01) ( Fig. 2a) . For a subset of the subjects, we received brain tissues from both areas 7 and 8 from the same participants. As a result of dependent data in the repeated measurements from both areas 7 and 8 for the same participants, we used a mixed model to adjust for variance. We found that there was no statistical difference between the two brain regions. There were no statistical differences between brain regions and mtDNA levels in gray matter (Fig. 2b) .
By quantifying the 'common deletion', we compared levels of mitochondrial injury in white matter from areas 8, 9, and 46. We found that area 46 had the highest relative proportion of mitochondrial injury when compared with area 8 (P < 0.01) and area 9 (P ¼ 0.01) ( Fig. 2c) . Again, for a subset of the subjects with brain tissue samples from both areas 7 and 8, we used a mixed model to adjust for variance and found that there were no statistical differences. We did not find any statistical difference between brain regions and mitochondrial injury in gray matter (Fig. 2d ), even though higher levels of 'common deletion' were present in gray matter rather than white matter. However, we still found that white matter had greater differences between the brain regions and the proportions of mtDNA with the 'common deletion' when compared with gray matter in a mixedmodel analysis.
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Levels of mtDNA and mitochondrial injury in patient groups
Significant differences in mtDNA copy number and mitochondrial injury were found only in white matter rather than gray matter. In addition, we collected the largest amount of samples from area 8. Because of these reasons, we decided to focus our analysis on white matter from area 8. In this brain region, participants in the HIVþMETHþ group had significantly higher levels of mtDNA per cell when compared with HIVþMETHÀ (P ¼ 0.02) and HIVÀMETHÀ (P < 0.01) ( Fig. 3a) . HIVþMETHþ group showed significantly less mitochondrial injury when compared with the HIVþMETHÀ group (P ¼ 0.02) and HIVÀMETHÀ group (P ¼ 0.08) (Fig. 3b ). When we compared the three study groups by analysis of variance followed by the Tukey adjustment, we again found significantly less mitochondrial injury in the HIVþMETHþ group when compared with the HIVþMETHÀ (P ¼ 0.01) and HIVÀMETHÀ groups (P ¼ 0.06). However, we did not find any significant differences in the levels of mtDNA with these additional tests.
Mitochondrial injury is associated with age
Since the relative proportion of mtDNA carrying the 'common deletion' is known to be associated with increasing age and mortality [34, 35] , we performed fixedeffect regression analysis to determine the association of both measurements of mtDNA copy number and mitochondrial injury with age. After correcting for the subset with measurements from both areas 7 and 8, we found that there was no association between the levels of mtDNA per cell and age (Fig. 3c) ; however, a higher abundance of the 'common deletion' was associated with increasing age (Fig. 3d , P ¼ 0.03).
MtDNA and mitochondrial injury is associated with cognitive function
We performed a multivariate analysis to evaluate the association of levels of mtDNA and mitochondrial injury with GDS while adjusting for age and brain region. We used recursive partitioning to determine the effects of age and brain region in the model. If a variable did not contribute significantly to the model, it was removed from the model. In the HIVþMETHþ group, we found d) the abundance of the 'common deletion' in different brain regions in white and gray matter. Significant differences in levels of mtDNA and the abundance of the 'common deletion' was seen in white matter. In addition, BA46 showed the highest levels of mtDNA and mitochondrial injury compared with BA8 and BA9. There was no statistical difference in levels of mtDNA and mitochondrial injury in gray matter. BA, Brodmann area; ND2, NADH dehydrogenase 2. that a higher abundance of 'common deletion' was associated with lower GDS (P < 0.01); however, in the HIVþMETHÀ group, higher abundance of 'common deletion' was associated with higher GDS (P < 0.01) ( Table 2) .
HIV DNA in brain tissue is associated with mitochondrial injury
We performed a multivariate analysis to evaluate the association between levels of HIV DNA and mitochondrial injury while adjusting for age and brain region. In both HIVþ groups, we found that higher abundance of 'common deletion' was associated with higher levels of HIV copies per million cells (P < 0.01) found in brain tissue ( Table 2 ). We did not find any associations between levels of HIV DNA and mtDNA.
Levels of cell free mtDNA, soluble and inflammatory markers in cerebral spinal fluid
There were no significant associations between cell-free mtDNA in CSF, in relation to subject groups, GDS, or other clinical and immunological variables. There were also no significant associations between soluble and inflammatory markers, such as sCD14, sCD163, NF-L, and neopterin, in relation to subject groups and other clinical and immunological variables.
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Discussion
This is the first study to measure and compare the levels of mtDNA and the abundance of the 'common deletion' in brain tissue in HIV-infected individuals with or without reported history of past METH use. We found significant differences in levels of mtDNA per cell and the abundance of 'common deletion' in white matter of brain tissue in HIVþMETHþ and HIVþMETHÀ groups. We also found a relationship between the abundance of the 'common deletion' with levels of HIV in brain tissue. Previous studies have shown that high levels of mitochondrial injury and cell death are associated with increased environmental stress, increased production of ROS, and decreased respiration, Ca 2þ regulation, and electron transport chain activity [36, 37] . A significant increase in ROS is associated with oxidative DNA damage and mtDNA mutations, causing a chain of events that would lead to mitochondrial injury and cell death [38] . In cultured media, toxicity is directly related to Ca 2þ influx, as Ca 2þ is a major determinant of glutamate receptor excitotoxicity [39] . A greater abundance of the 'common deletion' could indicate a larger amount of mitochondrial injury because of oxidative stress, which may be worsened by HIV infection.
Highest levels of mtDNA and mitochondrial injury were seen in the white matter of Brodmann area 46 when compared to areas 7, 8, and 9. We found that only brain tissue from white matter demonstrated statistically significant variation in mtDNA levels and mitochondrial injury. This is supported by previous observations demonstrating that glutamate excitotoxicity and downstream free radical attack by ROS frequently occurs in glial cells like oligodendrocytes and myelinated axons present in white matter [40, 41] , whereas gray matter primarily contains unmyelinated axons [42] . Observable differences in mtDNA levels and injury may vary more between myelinated and unmyelinated axons. In addition, we found that higher abundance of 'common deletion' was associated with higher levels of HIV in brain tissue, perhaps indicating a relationship between HIV viral loads in the brain with mitochondrial injury.
We observed that levels of mtDNA and mitochondrial damage in white matter were highest among HIVinfected without METH individuals, but lowest in HIVinfected with METH users. In addition, we observed that a higher proportion of mtDNA carrying the 'common deletion' was associated with better neurocognitive function, (i.e. lower GDS), in HIV-infected METH users, but worse neurocognitive function in HIV-infected non-METH users. The reason for the reduced levels of mitochondrial injury in METH users remains unclear, but possible explanations include: A sampling bias from where the brain tissue was sampled; induction of mitophagy by METH -thus the measureable amount of mitochondrial injury is reduced because of selective degradation of damaged mitochondrial DNA [43, 44] ; neuroprotection by METH -previous work has shown that METH may mediate neuroprotection at low doses through moderate activation of dopamine receptors via the phosphoinositol-3 kinase and protein kinase B (Akt) pathways, both of which are responsible for apoptosis and cell proliferation [45] , whereas dopamine receptor D2 activation plays an important role in protecting the brain against glutamate cytotoxicity through Akt signaling and upregulation of Bcl-2 expression, an antiapoptotic protein [46, 47] ; and reduced ARTexposure -although HIV-infected participants (HIVþMETHÀ, HIVþMETHþ) in our study were on ART until the last visit prior to death, previous studies have shown that HIV-infected METH users are prone to medication nonadherence [48] . ART has been known to induce oxidative stress [49, 50] , and increase mitochondrial toxicity, particularly with the use of nucleoside reverse transcriptase inhibitors [51] . Therefore, reduced ART exposure could lead to lower levels of mitochondrial injury.
As with any evaluation of a clinical cohort, this study has several limitations. Primarily, all participants were enrolled into the NNTC at the time of death. Antemortem clinical data were only abstracted from medical records and sometimes acquired through family reports. For example, a urine toxicology test for amphetamine was not administered to everyone in the HIVþMETHþ group. We cannot adequately determine the length of history of the participants' exposure to METH, whether it is past, current, or lifetime, abuse, or dependence. We were also limited to only the four Brodmann areas that were provided in our study as well as the number of available samples for each group. In addition, in our analysis of HIV viral loads and mitochondrial injury, not all the participants had undetectable HIV viral loads and were in different stages of infection during the time clinical and neuropsychological assessments were administered. The small numbers in our cohort limited our ability to correct for other potential confounders, such as disease stage, ART use, and other demographic factors.
In conclusion, our data indicate that levels of mtDNA per cell and the abundance of 'common deletion' are significant in white matter of brain tissue in Brodmann area 46 when compared with areas 7, 8, and 9. Participants who were HIVþMETHþ had the lowest levels of mitochondrial injury per cell in white matter when compared with the HIVþMETHÀ and HIVÀMETHÀ groups, as well as lowest mtDNA copy number. There was also a significant association between greater mitochondrial injury with higher HIV DNA levels in brain tissue. As expected, increased mitochondrial injury was associated with worse neurocognitive function in HIV-infected individuals. However, in those individuals using METH, an opposite effect was seen. Further work is needed to clarify the relationships between the presence of mitochondrial injury and neurocognitive function in HIV-infected individuals and users of METH.
